A sponge-like gold nanoparticle platform could deliver faster, more accurate, and less invasive ovarian cancer diagnostics.

SAN FRANCISCO, May 22, 2025 /PRNewswire/ -- OncoSwab, a biotechnology company focused on early detection of cancer through non-invasive molecular testing, today announced it has entered into a ...

InterVenn Biosciences, a precision diagnostics company advancing liquid biopsy with glycoproteomics, and Aranscia, a global provider of award-winning clinical workflow and diagnostic technology ...

For individuals facing fear, uncertainty and repeated procedures associated with recurrent low-grade intermediate-risk bladder tumors, timely access to treatment can be critical. ZUSDURI, the first ...

Ductal carcinoma in situ (DCIS) is a non-invasive breast condition found in nearly 20% of breast cancer diagnoses, but a growing number of doctors and medical experts are questioning whether the term ...

ZUSDURI shows promising long-term efficacy in treating low-grade intermediate-risk bladder cancer, maintaining event-free survival in patients. UroGen Pharma Ltd. announced findings published in the ...

Florian Willomitzer (left) and Madabhushi Balaji align their Synthetic Wavelength Imaging lab bench prototype to image non-melanoma skin cancer. The final prototype will be implemented in a portable ...

Detailed price information for Cg Oncology Inc (CGON-Q) from The Globe and Mail including charting and trades.